8/8/2019 Pathology of Extra Hepatic HCV Manifestations
1/21
Pathogenesis of EHMs of HCV
Ahmed Alwassief, MD
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
2/21
HCV has emerged as a major worldwide publichealth problem. HCV infection affects
approximately 3% of the world population.Currently Hepatitis C infection is considered Asystemic disease with extrahepaticmanifestationsAccording to different studies, 40-74% of patientsinfected with HCV might develop at least oneEHM during the course of the disease.
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
3/21
Classifications
HCV related EHDs
Prevalence and pathogenesis Clinical
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
4/21
Evidence based classificationA: Association on the basis of high
prevalence and clear pathogenesisMC (complete or incomplete clinicalsyndrome)
B: Associations defined on the basis of higher prevalences than in controls
B-cell NHLMonoclonal gammopathiesPorphyria cutanea tardaLichen planus
C: Associations to be confirmed Autoimmune thyroiditisThyroid cancer
Sicca syndromeAlveolitis-lung fibrosisDiabetes mellitusNon-cryoglobulinaemic
nephropathiesAortic atherosclerosis
D: Anecdotal observations
PsoriasisPeripheral/central neuropathiesChronic polyarthritisRheumatoid arthritisPolyartheritis nodosaBechets syndrome
Poly/dermatomyositisFibromyalgiaChronic urticariaChronic pruritusKaposis pseudo-sarcomaVitiligo
CardiomyopathiesMooren corneal ulcer Erectile dysfunctionsNecrolytic acral erythema
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
5/21
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
6/21
Pathogenesis
HCV is both hepato- and lympho-tropic . The infectionof the lymphoid tissue is a reservoir of the virus inthe host, that is important for the persistence of theinfection .
1. Dysregulation of anti-idiotype networks and expansion of autoantibody-producing B-cells.
2. Molecular mimicry between viral and self-antigens.3. Immune complex formation {fragments of IgG or
complement components }.4. Th1/Th2 response imbalance and autoantibody
production.5. Host genetic factors (e.g., HLA) .
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
7/21
Consequences of immune system dysfunction
HCV infection induce nonspecific autoimmune reactions , asdemonstrated by the high prevalence of various non-organ-specific autoantibodies, usually in low titers. The clinicalsignificance of most of these autoantibodies is not clear.Cryoglobulins
Rheumatoid factor Antinuclear antibodies (ANA)Anticardiolipin (aCL)Antithyroid (ATA)
Anti-liver/Kidney/Microsomal antibodies (anti-LKM).HCV/anti-HCV immune complex formation and deposition
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
8/21
MC
Mixed cryoglobulinemia (MC) is the most knownand studied syndrome associated with HCVInfection.Cryoglobulins are usually found at low
concentrations and only 10% of patients aresymptomatic.The prevalence of MC increases with the duration of the disease
MC and liver damage . Presence and level of cryoprecipitate is a negative prognostic factor inHCVAfter viral clearance Improvement of clinical MC is
reported in 50 to 70% of cases.
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
9/21
Strong associations exist between HCV and mixed cryoglobulinemiatypes II and III.
some studies also suggest an association between type I and HCV, in particular the HCV 2a/c genotype.
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
10/21
Sk in : Is commonly involved (95% of cases) withacutaneous vasculitis (leukocytoklastic vasculitis).
Kidney: is frequently involved (35-60%) (MPGN)Renal biopsy demonstrates immunocomplexesdeposits of IgG, IgM with rheumatoid factor (RF)activity and C3 in capillary loops.Clinically the
patient may present by haematuria and protienuriaIn 20% of patients the disease is characterized byrecurrent episodes of nephritic syndrome
Neuropathy: In 7 up to 90% of cases of MC there
is a peripheral . Neuropathy is mostly sensory.
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
11/21
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
12/21
Treatment:IFN+ RibavirinSteroidRituximab: Monoclonal antibody againstCD 20, a B-cell specific surface antigen inMC with renal disease
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
13/21
L ymphoproliferative disorders
A frequent reported association is that between HCV infection andnon-Hodgkin lymphoma (NHL) .The MC may be the intermediary disorder. Some persistent forms of cyoglobulinemia can switch over to a more aggressive hematologicaldisorder in up to 11% of cases.
Pathogenesis of L ymphoproliferative disorders is a 3 steps process1. Clonal B cell expansion of immunoglobulin (cryoglobulin)-secreting
lymphocytes.2. Combination of genetic and environmental factors result in a
mutational event .3. Activation of oncogenes and resulting in NHL.
Another possibility is the inhibition of apoptosis of HCVinfectedlymphocytes by t(18;14) traslocation. IFN treatment resulted in theloss of t(18;14) in 86% of HCV-infected patients with no lymphoma.
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
14/21
Several investigators also demonstrated a stronglink between HCV infection and mucosa-
associated lymphoid tissue (MALT) lymphoma.
HCV RNA has been isolated in the gastric mucosaof patients with MALT lymphoma, raising the
possibility that HCV may play a role in its pathogenesis.
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
15/21
D ermatological manifestations
Porphyria cutanea tardaThis is caused by the reduction of hepatic
uroporphyrinogen decarboxylase activity, resulting inan over production and build up of the proteinuroporphyrinogen in the blood and urine of patients
HCV seems to replicate in the epithelial (skin andmucosal) cells. Some studies suggest an association
between and lichen planus.
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
16/21
E ndocrinal manifestations
ThyroidThyroid disease (usually hypothyroidism) is morecommonly seen in people with HCV than in the general
population . About 13% of HCV infected patients havehypothyroidism and up to 25% have thyroid Antibodies
Sub-clinic hypothyroidism was observed in 29% of
patients with chronic HCV infection and particularly inthose with MCSeveral studies reported a high prevalence of papillarythyroid cancer in patients with HCV infection.
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
17/21
D iabetes mellitus
Diabetes mellitus (T2DM) is found morecommonly in patients with chronic HCVinfection than in the general population .
Pathogenesis may include1. Insulin resistance may lead to the development of
T2D in HCV+ patients.2. HCV infection was present in human pancreatic
beta-cells, which was associated withmorphological cell changes and reduced glucose-stimulated insulin release in vitro.
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
18/21
Is it over yet?
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
19/21
Take home note
EHMs are common but may be subclinicalComplete screening of HCV positive patients at
first examination should stress on finding EHMslike:Purpura, asthenia , arthralgias , arthritis,xerostomia, Raynaud, dermatiti s, cutaneous ulcers,neuromuscular abnormalities, oedema, and
proteinuria. U rin examination, Blood glucose test areimportant screening tests in HCV patients
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
20/21
8/8/2019 Pathology of Extra Hepatic HCV Manifestations
21/21
Top Related